Partner Therapeutics, Inc.
Lexington, MA
- UEI
- J33MSDBJZMC6
- CAGE
- 7ZTL0
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 19 Muzzey St, Lexington, MA 02421, USA
- Website
- partnertx.com
- Founded
- 2017
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $64,333,173 |
| FY2025 | $39,113,908 |
| FY2024 | $35,192,691 |
| FY2023 | $22,947,301 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $49,999,198 | |
| 2 | Department of the Army | $14,098,498 | |
| 3 | Department of Veterans Affairs | $235,477 |
Contract vehicles
Expired vehicles (1)
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Chartwell RX LLC | Congers, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Genentech Usa, Inc. | South San Francisco, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Merz Pharmaceuticals, LLC | Raleigh, NC | 325412 Pharmaceutical Preparation Manufacturing |
| ELI Lilly And Company | Indianapolis, IN | 325412 Pharmaceutical Preparation Manufacturing |
| Exelan Pharmaceuticals Inc. | Boca Raton, FL | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Partner Therapeutics, Inc., a for-profit biopharmaceutical manufacturer based in Lexington, Massachusetts, supplies pharmaceutical products and develops medical countermeasures to the federal government as a prime contractor across the Department of Health and Human Services, Department of Veterans Affairs, and Department of the Army, competing full-and-open with no set-aside designations and without subcontractors.
Partner Therapeutics operates across two primary capability areas: pharmaceutical supply and development of therapeutics for medical countermeasures. On the supply side, the company holds a GSA Federal Supply Schedule contract (Pharmaceuticals and Drugs, FSS-61-IB) with a ceiling of $15.8 million through August 2028, under which it delivers Leukine (sargramostim) and other emergency medications to federal customers. On the development side, Partner Therapeutics conducts advanced research and development on medical countermeasures for defense and public health threats. The company's federal portfolio centers on Leukine supply and regulatory advancement, with recent work including a $133.5 million delivery order from HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) placed in September 2023 for Leukine 250mcg vial injectables through March 2027; a $47.9 million Other Transaction Agreement awarded by the Department of the Army's Joint Program Executive Office Chemical and Biological Defense in July 2026 for development of an auto-injector to enhance Leukine use as post-exposure prophylactic and treatment for warfighter radiation injuries, extending to September 2031; a $13.7 million definitive contract from HHS ASPR awarded in September 2024 for advanced development of Leukine, monocyte human leukocyte antigen-DR biomarkers, and sepsis diagnostic advancement through September 2028; and a $22.3 million Other Transaction IDV awarded by the Joint PEO Chemical and Biological Defense in January 2022 under Project Kickoff to support FDA approval for Leukine in sulfur mustard injury treatment.
Customer concentration is extreme. HHS ASPR accounts for nine awards and $919.5 million combined potential value (91% of the portfolio), driven primarily by large Leukine supply delivery orders on the GSA Schedule. The Department of the Army's Joint PEO Chemical and Biological Defense holds two awards worth $70.3 million in combined potential value. Veterans Integrated Service Networks 6 and 12 together hold seven awards valued at $19.4 million, consisting primarily of small emergency pharmaceutical delivery orders at $36,000 to $73,000 each. All eighteen awards are prime contracts; Partner Therapeutics subcontracts minimally, with an average sub-hours share of 5% across SCI-reported prime contracts and only one named subcontractor across the portfolio.
Partner Therapeutics holds seats on two parent vehicles: the GSA Pharmaceuticals and Drugs Federal Supply Schedule (six task orders, $192.8 million combined potential value) and an HHS Colony Stimulating Factor vehicle (two task orders, $51.6 million combined potential value). Award activity was concentrated in 2023 (three awards) and 2026 (five awards), with only one award recorded in 2024. Two awards with combined potential value of $147.2 million reach ultimate completion within the next twenty-four months, creating recompete exposure for those vehicles. The company's federal portfolio carries a combined potential value of $1.01 billion, with $368.1 million obligated to date (36% of potential value), reflecting the nascent phase of large development agreements with completion dates extending to 2031. SCI-reported federal service contract activity is minimal; the dataset shows 0.4 FTEs across FY2024 only, indicating that Partner Therapeutics' federal revenue is predominantly driven by product supply and development contracts classified outside SCI's reporting scope.
Quick answers
Is Partner Therapeutics, Inc. registered in SAM.gov?
Yes. Partner Therapeutics, Inc.'s SAM.gov registration is active through August 4, 2027.
Which contract vehicles does Partner Therapeutics, Inc. hold?
Partner Therapeutics, Inc. holds a place on 2 federal contract vehicles, including FSS-61-IB.
How much has Partner Therapeutics, Inc. received in federal contracts?
Federal contracts obligated $39,113,908 to Partner Therapeutics, Inc. in fiscal year 2025 and $161,587,073 in fiscal years 2023 through 2027.
How does Partner Therapeutics, Inc. rank among federal contractors?
Partner Therapeutics, Inc. ranked #13 in NAICS 325412, #16 in NAICS 3254 and #19 in PSC 6515 in FY2025.
What is Partner Therapeutics, Inc.'s most recent federal award?
Partner Therapeutics, Inc.'s most recent federal contract award is Bizengri medication (36C24626N1034), from Veterans Integrated Service Network 6 (VHA), on September 4, 2026.
On GovTribe
See Partner Therapeutics, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors